Loading...
Although the efficacy of clopidogrel plus aspirin for treating acute coronary syndromes (ACS) is well established, considerable uncertainty remains about dosing. Investigators for the manufacturer-sponsored CURRENT–OASIS 7 trial employed a 2×2 factorial design to examine the effects of doubling the standard loading dose and first-week maintenance dose of clopidogrel (from 300 to 600 mg and from 75 to 150 mg, respectively), and compared the effects of high-dose (300–325 mg/day) versus low-dose (75–100 mg/day) aspirin. All 25,086 patients (mean age, 61; 27% women) had ACS and were scheduled for coronary angiography with percutaneous coronary intervention (PCI) as indicated within 72 hours after randomization, and all received a loading aspiri…